Moderna submits regulatory application to the european medicines agency for its updated covid-19 vaccine

The filing follows the recommendation from regulators and global public health bodies to develop monovalent xbb.1.5 covid-19 vaccines pending approval, moderna's updated covid-19 vaccine will be available for fall vaccination with ample and timely supply preliminary clinical data show that the company's xbb1.5 monovalent vaccine induces an immune response against viruses of the xbb lineage cambridge, ma / accesswire / july 3, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has submitted a regulatory application to the european medicines agency (ema) for its updated covid-19 vaccine encoding the spike protein for the xbb.1.5 sublineage of sars-cov-2. "we are proud to announce this filing for our updated covid-19 vaccine and continue to support the european union in protecting citizens against covid-19," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking